47- Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, et al.
Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin
Gastroenterol Hepatol. 2011;9(8):670–8.e3. - Lichtenstein GR, Thomsen OO, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, et al.
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s
disease for up to 18 months. Clin Gastroenterol Hepatol. 2010;8(7):600–9. - Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, et al. Long-term
safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results
from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014;40(8):903–16. - Hebuterne X, Lemann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, et al. Endoscopic improve-
ment of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease fol-
lowing treatment with certolizumab pegol. Gut. 2013;62(2):201–8. - Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, et al. Efficacy and safety
of certolizumab pegol induction therapy in an unselected Crohn’s disease population: results
of the FACTS survey. Inflamm Bowel Dis. 2010;16(6):933–8. - Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, et al. Infliximab
heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig
Liver Dis. 2004;36(5):342–7. - Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, et al. The
impact of infliximab induction therapy on mucosal healing and clinical remission in Polish
pediatric patients with moderate-to-severe Crohn’s disease. Eur J Gastroenterol Hepatol.
2012;24(5):495–500. - Crandall W, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, et al. Infliximab therapy
in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr
Gastroenterol Nutr. 2009;49(2):183–90. - Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al.
Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children.
Gastroenterology. 2012;143(2):365–74.e2. - Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort
of Crohn’s disease patients. Scand J Gastroenterol. 1995;30(7):699–706. - D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early com-
bined immunosuppression or conventional management in patients with newly diagnosed
Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–7. - St Charles M, Smith SR, Beardsley R, Fedder DO, Carter-Pokras O, Cross
RK. Gastroenterologists’ prescribing of infliximab for Crohn’s disease: a national survey.
Inflamm Bowel Dis. 2009;15(10):1467–75. - Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness
of adverse effects of Infliximab:CD: a health survey of gastroenterologists. Dig Dis Sci.
2007;52(8):1798–805. - Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined
immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised
controlled trial. Lancet. 2015;386(10006):1825–34. - Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active
Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology.
2001;121(5):1088–94. - Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, et al. Onercept
for moderate-to-severe Crohn’s disease: a randomized, double-blind, placebo-controlled trial.
Clin Gastroenterol Hepatol. 2006;4(7):888–93. - Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, et al. An
engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized
double- blind placebo-controlled trial. Gastroenterology. 2001;120(6):1330–8. - Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. CDP571, a
humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent
3 Antitumor Necrosis Factor Agents in Crohn’s Disease